Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

The latest verdict – in a federal appeals court – has upheld the validity of a key patent on sitagliptin, the active ingredient in Januvia, as well as metformin combinations Janumet and ...

Avanir Pharmaceuticals has entered into an exclusive, multi-year agreement with Merck to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products ...

Januvia (sitagliptin) Onglyza (saxagliptin) Tradjenta (lingliptin) Nesina (alogliptin) Glucagon-Like Peptide-1 Agonists (GLP-1s) Glucagon-like peptide-1 agonists (GLP-1s) can increase the release ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

A recently published study examined the effects of adding sitagliptin—an inhibitor of dipeptidyl peptidase 4—to therapy for patients with type 2 diabetes mellitus who were inadequately ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...